Single Ventricle Reconstruction Extension Study (SVR II) - Pediatric Heart Network

Heart Defects Clinical Trial

— SVRII  

Official title:

Single Ventricle Reconstruction Extension Study (A Study Conducted by the Pediatric Heart Network)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02110823
• Other study ID #: U10HL068270-4a
• Secondary ID: U10HL068270
• Status: Active, not recruiting
• Start date: March 2008
• Est. completion date: June 2025

Study information

• Verified date: February 2024
• Source: Carelon Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The Single Ventricle Reconstruction (SVR) Trial looked at how infants with single ventricle heart defects did after the first stage of surgery (Norwood operation). Infants enrolled in the trial got one of two kinds of shunts during the Norwood; a modified Blalock-Taussig shunt (MBTS) or right ventricle to pulmonary artery shunt (RV-to-PA shunt).

The purpose of this study is to learn if children (2-6 years of age) who were enrolled in the SVR Trial do better with one of the two shunts (MBTS or RV-to-PA) in the years after surgery.

Description:

Among critical congenital heart lesions, hypoplastic left heart syndrome (HLHS) and related single right ventricle (RV) anomalies are associated with the highest morbidity and mortality. The first stage in palliation for patients with these defects is the Norwood procedure. The essential components of the Norwood procedure include (1) an atrial septectomy, (2) anastomosis of the proximal pulmonary artery to the aorta with homograft augmentation of the aortic arch, and (3) establishment of a source of pulmonary blood flow, with either a modified Blalock-Taussig shunt (MBTS) or the right ventricle to pulmonary artery (RV-to-PA) shunt. In May 2005, the Pediatric Heart Network began a multi-center, randomized trial, the Single Ventricle Reconstruction (SVR) Trial, comparing outcomes in subjects with HLHS or other single RV anomalies palliated using the Norwood procedure with either a MBTS or the RV-to-PA shunt. The primary outcome of this trial was freedom from death or cardiac transplantation by 12 months post-randomization.

The Single Ventricle Reconstruction Extension (SVR II) Study is an extension of the SVR Trial that compares clinical outcomes and RV performance following the RV-to-PA shunt versus MBTS modifications of the Norwood procedure in subjects at 6 years post-randomization. Data is collected annually between ages 2 and 6 years, as well as before and after the Fontan surgery. Vital status and medical history is ascertained annually until the last enrolled subject is 6 years old. Data is obtained through medical record review, phone interview with the parent or guardian, electrocardiography (ECG), core laboratory analysis of echocardiographic images and Holter monitors, and completion of questionnaires regarding neurodevelopmental outcomes, behavior, health-related quality of life, and family functioning. The primary outcome variable in SVR II will be freedom from death or cardiac transplantation at 6 years post-randomization. All subjects who were randomized in the SVR trial will be included in analysis of this endpoint.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 325
• Est. completion date: June 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 6 Years

Eligibility

Inclusion Criteria:

• Randomized subject in the Single Ventricle Reconstruction Trial

Exclusion Criteria:

• No subjects enrolled in the the original SVR Trial will be excluded from analysis of the primary endpoint

Related Conditions & MeSH terms

• Heart Defects
• Univentricular Heart

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Carelon Research	National Heart, Lung, and Blood Institute (NHLBI)

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Freedom from death and cardiac transplantation at 6 years post-randomization.		Assessed annually until the last enrolled subject reaches 6 years of age.
Secondary	Direct and indirect measures of right ventricle (RV) systolic and diastolic function.	RV ejection fraction by echocardiogram pre-Fontan and at 6 years.; RV fractional area change pre-Fontan and at 6 years post-randomization.; Severity of tricuspid regurgitation by echocardiogram pre-Fontan and at 6 years.; Heart Failure Class pre-Fontan and at 3, 4, 5, and 6 years.; Somatic growth pre-Fontan and annually from ages 2-6 years.	Pre-Fontan, and 6 years of age
Secondary	6 years post randomization		post procedure up to 6 years post randomization
Secondary	Incidence of arrhythmias.	Diagnosis of ventricular arrhythmias by 6 years.; Diagnosis of atrial arrhythmias by 6 years.	Assessed once, at 6 years of age
Secondary	Neurodevelopment.	Ages & Stages Questionnaires (ASQ)	Questionnaires completed at ages 3, 4, 5, and 6 years
Secondary	Behavior	Behavior Assessment System for Children, Second Edition (BASC-2); Vineland Adaptive Behavior Scales	Questionnaires completed at ages 3, 4, 5, and 6 years
Secondary	Health-related quality of life	Pediatric Quality of Life Inventory (PedsQL); Children's Health Questionnaire Parent Form 50-Item (CHQ-PF50) Physical and Psychosocial Function Summary	Questionaires completed at ages 3, 4, 5 and 6 years
Secondary	Family function	Impact on Family Scale Functional States II-R	Questionnaires completed at ages 3, 4, 5, and 6 years